SOLANA BEACH, Calif. and REDWOOD CITY, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors ...
(RTTNews) - eFFECTOR Therapeutics, Inc. (EFTR) announced Thursday topline results from the primary analysis of the randomized Phase 2 KICKSTART trial which tested tomivosertib or placebo, each ...
Boehringer Ingelheim has received a breakthrough therapy designation from the US Food and Drug Administration (FDA) for survodutide as a treatment for non-cirrhotic metabolic dysfunction-associated ...
Zotatifin continues to show favorable activity profile, including two confirmed partial responses (PR) among seven heavily pretreated subjects who received zotatifin, fulvestrant and abemaciclib ...
The mid-stage studies will assess the safety, acceptability, and pharmacokinetics of lenacapavir injection every six months. FDA has already approved Lenacapavir for HIV treatment, in combination with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback